Clopidogrel Bisulfate Powder CAS 120202-66-6 Raw Material

CAS:120202-66-6

MF:  C16H16ClNO2S.H2O4S

MW: 419.9

EINECS: 1806241-263-5

Specification​: 99% min Clopidogrel Bisulfate

Sample:  Clopidogrel Bisulfate Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Clopidogrel Bisulfate Powder Usage and Synthesis.

Clopidogrel Bisulfate Powder is an antiplatelet agent that is widely used clinically in the treatment of myocardial infarction, ischemic stroke and Clopidogrel Bisulfate Raw Material is used clinically for the prevention and treatment of cardiac, cerebral and Clopidogrel Bisulfate Raw Material is used clinically for the prevention and treatment of cardiac, cerebral and arterial circulatory disorders caused by high platelet aggregation and for the prevention of atherosclerotic thrombotic events. Clopidogrel Bisulfate Powder is used as an anticoagulant, a P2Y12 receptor inhibitor.

Uses and functions of Clopidogrel Bisulfate Powder.

Clopidogrel Bisulfate Powder is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi- Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation Many countries have already used it, including the United States, the United States, the United States, and the United States. 

Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. 

Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment.

Clopidogrel sulfate tablets actually refer to clopidogrel hydrogen sulfate tablets, which are mainly used for prevention and treatment. It can be used for transient ischemic attack, cerebral infarction, cerebral embolism, coronary artery disease, angina pectoris and acute myocardial infarction. In the process of application, the usual dosage for adults is once a day, one tablet at a time.

If the condition is more serious, it can be used twice a day, one tablet at a time. In the process of application, individual adverse reactions may occur, which may lead to abdominal pain, indigestion, constipation or diarrhea rash, that is, bleeding of the skin mucosa. In rare cases, it may cause leukopenia and granulocytopenia.

It is contraindicated in patients with allergies to the drug who have had recent active bleeding, such as peptic ulcers, or intracranial hemorrhage. Patients using the drug need to be informed if they undergo surgery and need to stop the drug in advance. Patients with liver damage and bleeding tendency should be used with caution, and patients with hepatic insufficiency generally do not need to adjust the dose when using the drug.

Pharmacological Effects of Clopidogrel Bisulfate Powder.

This product is a platelet aggregation inhibitor that selectively inhibits the binding of ADP to platelet receptors and subsequently inhibits the activation of the ADP-glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. It also inhibits non-ADP-induced platelet aggregation, without affecting phosphodiesterase activity. This product affects platelet lifespan by irreversibly altering platelet ADP receptors.

Clopidogrel sulfate is a novel and highly effective antiplatelet drug, which is clinically used in the treatment of atherosclerotic disease, acute coronary syndrome and thrombotic complications. Compared with other antiplatelet drugs, clopidogrel sulfate has the advantages of strong efficacy, low cost and low side effects. Clopidogrel sulfate in combination with aspirin is gradually becoming the standard of antithrombotic therapy in cardiovascular diseases.